Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Result of AGM

20th Jan 2022 10:50

RNS Number : 1112Z

IXICO plc

20 January 2022

IXICO plc

("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

	RESOLUTION	VOTESFOR	%	VOTESAGAINST	%	VOTESTOTAL	% ISC VOTED	VOTESWITHHELD
1	Reports and Accounts	30,181,599	99.99	800	0.01	30,184,099	62.69	1,700
2a	Re-election of Charles Spicer	30,166,631	99.97	10,107	0.03	30,184,099	62.69	7,361
2b	Re-election of Grant Nash	30,166,931	99.97	9,807	0.03	30,184,099	62.69	7,361
3	Re-appointment of Auditors	29,764,948	98.66	405,081	1.34	30,184,099	62.69	14,070
4	Allotment of Securities	30,172,562	99.97	10,037	0.03	30,184,099	62.69	1,500
5	* Disapply Pre-Emption Provisions	30,149,112	99.89	33,487	0.11	30,184,099	62.69	1,500

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution.

For further information please contact:

IXICO plc			+44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer

Cenkos Securities PLC (Nominated adviser and sole broker)				+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson (Sales)

Walbrook PR Ltd	+44 (0)20 7933 8780
Paul McManus / Lianne Applegarth /		[email protected]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IxicOplc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBKKBQKBKDADB

Related Shares:

FTSE 100 Latest

Value8,809.74

Change53.53